Immunotherapeutics for nosocomial infections

Expert Opinion on Investigational Drugs

Volumn 13, Issue 6, 2004, Pages 673-679

  Patti, Joseph M ^a  

^a Inhibitex Inc   (United States)

Author keywords

Active immunisation; Antibody; Bacteraemia; Methicillin resistant; Monoclonal antibody; Nosocomial infection; Passive immunisation; Staphylococcus aureus

Indexed keywords

ALTASTAPH; AUREXIS; AUROGRAB; BSYX A 110; CHIMERIC ANTIBODY; GLYCOCONJUGATE; HU 96110; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; INH A 21; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 12 9; PNEUMOCOCCUS VACCINE; RECOMBINANT ANTIBODY; STAPHVAX; TEFIBAZUMAB; UNCLASSIFIED DRUG; VACCINE; VANCOMYCIN; VERONATE;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; DRUG HALF LIFE; DRUG STRUCTURE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; IMMUNOTHERAPY; NONHUMAN; PREVALENCE; REVIEW; SIDE EFFECT; TACHYCARDIA;

ADHESINS, BACTERIAL; ATP-BINDING CASSETTE TRANSPORTERS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; CROSS INFECTION; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; LIPOPOLYSACCHARIDES; POLYSACCHARIDES, BACTERIAL; TEICHOIC ACIDS;

EID: 3042769691     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.6.673     Document Type: Review

References (51)

1. HALL M, LAWRENCE L: Ambulatory surgery in the United States (1996). Advance data from vital and health statistics. In: National Center for Health Statistics (Volume 300). Hyattsville, MD (1998).
2. HORAN TC, CULVER DH, GAYNES RP, JARVIS WR, EDWARDS JR, REID CR: Nosocomial infections in surgical patients in the United States, January 1986 - June 1992. National Nosocomial Infections Surveillance (NNIS) System. Infect. Control Hosp. Epidemiol. (1993) 14(2):73-80.
3. BOYCE JM, POTTER-BYNOE G, DZIOBEK L: Hospital reimbursement patterns among patients with surgical wound infections following open heart surgery. Infect Control Hosp. Epidemiol (1990) 11(2):89-93.
4. BOYCE JM, DZIOBEK L, POTTER-BYNOE G: Reimbursement for nosocomial infections. Ann. Intern. Med. (1988) 108(5):776.
5. KIRKLAND KB, BRIGGS JP, TRIVETTE SL, WILKINSON WE, SEXTON DJ: The impact of surgical-site infections in the 1990s: attributable mortality, excess length of hospitalization, and extra costs. Infect. Control Hosp. Epidemiol. (1999) 20(11):725-730.
6. WHITEHOUSE JD, FRIEDMAN ND, KIRKLAND KB, RICHARDSON WJ, SEXTON DJ: The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost. Infect. Control Hosp. Epidemiol. (2002) 23(4):183-189.
7. CDC: National nosocomial infections surveillance (NNIS) system report, data summary from January 1990-May (1999) Issued June 1999. Am. J. Infect. Control (1999) 27:520-532.
8. RICHARDS M, EDWARDS J, CULVER D, GAYNES R: Nosocomial infections in medical intensive care units in the United States. Crit. Care Med. (1999) 27:887-892.
9. DUCKWORTH DH, GULIG PA: Bacteriophages: potential treatment for bacterial infections. BioDrugs (2002) 16(1):57-62.
10. DONABEDIAN H: Quorum sensing and its relevance to infectious diseases. J. Infect. Dis. (2003) 46(4):207-214.
11. VON EIFF C, KOKAI-KUN JF, BECKER K, PETERS G: In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood. Antimicrob. Agents Chemother. (2003) 47(11):3613-3615.
12. WU JA, KUSUMA C, MOND JJ, KOKAI-KUN JF: Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob. Agents Chemother. (2003) 47(11):3407-3414.
13. RICHARDS MJ, EDWARDS JR, CULVER DH, GAYNES RP: Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit. Care Med. (1999) 27(5):887-892.
14. MORIN CA, HADLER JL: Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. J. Infect. Dis. (2001) 184(8):1029-1034.
15. CHANG S, SIEVERT DM, HAGEMAN JC et al.: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. (2003) 348(14):1342-1347.
16. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51(26):565-567.
17. LEE JC: Staphylococcus aureus vaccine. In: New Bacterial Vaccines. Ellis R, Brodeur B (Eds), Kluwer Academic/Plenum (2003):283-293.
18. LEE J: Development of antistaphylococcal vaccines. Curr. Infect. Dis. Rep. (2001) 3:517-524.
19. PATTI JM, ALLEN BL, MCGAVIN MJ, HOOK M: MSCRAMM-mediated adherence of microorganisms to host tissues. Annu. Rev. Microbiol. (1994) 48:585-617.
20. FOSTER TJ, HOOK M: Surface protein adhesins of Staphylococcus aureus. Trends Microbiol. (1998) 6(12):484-488.
21. McDEVITT D, FRANCOIS P, VAUDAUX P, FOSTER TJ: Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol. Micro. (1994) 11(2):237-248.
22. McDEVITT D, VAUDAUX P, FOSTER TJ: Genetic evidence that bound coagulase of Staphylococcus aureus is not clumping factor. Infect. Immun. (1992) 60(4):1514-1523.
23. SIBOO IR, CHEUNG AL, BAYER AS, SULLAM PM: Clumping factor A mediates binding of Staphylococcus aureus to human platelets. Infect. Immun. (2001) 69(5):3120-3127.
24. MOREILLON P, ENTENZA JM, FRANCIOLI P et al.: Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect. Immun. (1995) 63(12):4738-4743.
25. QUE YA, HAEFLIGER JA, FRANCIOLI P, MOREILLON P: Expression of Staphylococcus aureus clumping factor A in Lactococcus lactis subsp. cremoris using a new shuttle vector. Infect. Immun. (2000) 68(6):3516-3522.
26. STUTZMANN MEIER P, ENTENZA JM, VAUDAUX P, FRANCIOLI P, GLAUSER MP, MOREILLON P: Study of Staphylococcus aureus pathogenic genes by transfer and expression in the less virulent organism Streptococcus gordonii. Infect. Immun. (2001) 69(2):657-664.
27. WOLZ C, GOERKE C, LANDMANN R, ZIMMERLI W, FLUCKIGER U: Transcription of clumping factor A in attached and unattached Staphylococcus aureus in vitro and during device-related infection. Infect. Immun. (2002) 70(6):2758-2762.
28. COLQUE-NAVARRO P, PALMA M, SODERQUIST B, FLOCK JI, MOLLBY R: Antibody responses in patients with staphylococcal septicemia against two Staphylococcus aureus fibrinogen binding proteins: clumping factor and an extracellular fibrinogen binding protein. Clin. Diagn. Lab. Immunol. (2000) 7(1):14-20.
29. VERNACHIO J, BAYER A, LE T et al.: Anti-clumping factor a immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob. Agents Chemother. (2003) 47(11):3400-3406.
30. HALL A, DOMANSKI P, PATEL P et al.: Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A. Infect. Immun. (2003) 71(12):6864-6870.
31. McCREA KW, HARTFORD O, DAVIS S et al.: The serine-aspartate repeat (Sdr) protein family in Staphylococcus epidermidis. Microbiology (2000) 146 (Pt. 7):1535-1546.
32. STOLL BJ, HANSEN N, FANAROFF AA et al.: Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics (2002) 110(2 Pt. 1):285-291.
33. BLOOM B, KUESER T, OELBERG D et al.: A Phase I, multicenter study and tolerance of a donor-selected staphylococcal immune globulin in very low birth weight infants. Pediatric Academic Societies Annual Meeting, Seattle, Washington (2003).
34. LESINSKI GB, WESTERINK MA: Vaccines against polysaccharide antigens. Curr. Drug. Targets Infect. Disord. (2001) 1(3):325-334.
35. THAKKER M, PARK JS, CAREY V, LEE JC: Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect. Immun. (1998) 66(11):5183-5189.
36. ADDERSON EE: Antibody repertoires in infants and adults: effects of T-independent and T-dependent immunizations. Springer Semin. Immunopathol. (2001) 23(4):387-403.
37. ANTTILA M, VOUTILAINEN M, JANTTI V, ESKOLA J, KAYHTY H: Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin. Exp. Immunol. (1999) 118(3):402-407.
38. FATTOM AI, SARWAR J, ORTIZ A, NASO R: A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun. (1996) 64(5):1659-1665.
39. LEE J, PARK J, SHEPHERD S: Protective efficacy of antibodies to the Staphylococcus aureus Type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect. Immun. (1997) 65:4146-4151.
40. NEMETH J, LEE JC: Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis. Infect. Immun. (1995) 63(2):375-380.
41. WELCH PG, FATTOM A, MOORE J et al.: Safety and immunogenicity of Staphylococcus aureus Type 5 capsular polysaccharide-pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis. J. Amer. Soc. Nephrol. (1996) 7(2):247-253.
42. SHINEFIELD H, BLACK S, FATTOM A et al.: Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Eng. J. Med. (2002) 346(7):491-496.
43. SCHMITT L, TAMPE R: Structure and mechanism of ABC transporters. Curr. Opin. Struct. Biol. (2002) 12:754-760.
44. HIGGENS C: ABC transporters: from microorganisms to man. Annu. Rev. Cell Biol. (1992) 8:67-113.
45. BURNIE JP, MATTHEWS RC, CARTER T et al.: Identification of an immunodominant ABC transporter in methicillin-resistant Staphylococcus aureus infections. Infect. Immun. (2000) 68(6):3200-3209.
46. FISCHER W: Physiology of lipoteichoic acid in bacteria. Adv. Microb. Physiol. (1988) 29:233-302.
47. GAO J, XUE E, ZUVANICH K, HAGHI K, MORRISON D: Commercial preparations of lipoteichoic acid contain endotoxin that contributes to activation of mouse macrophages in vitro. Infect. Immun. (2001) 69:751-757.
48. ELLINGSEN E, MORATH S, FLO T et al.: Induction of cytokine production in human T cells and monocytes by highly purified lipoteichoic acid: involvement of Toll-like receptors and CD14. Med. Sci. Monit. (2002) 8(5):BR149-BR156.
49. DE KIMPE SJ, KENGATHARAN M, THIEMERMANN C, VANE JR: The cell wall components peptidoglycan and lipoteichoic acid from staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc. Natl. Acad. Sci. USA (1995) 92(22):10359-10363.
50. KENGATHARAN KM, DE KIMPE S, ROBSON C, FOSTER SJ, THIEMERMANN C: Mechanism of Gram-positive shock: identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure. J. Exp. Med. (1998) 188(2):305-315.
51. WEISMAN L, MANDY G, GARCIA-PRATS J et al.: Safety and pharmockinetics of a human chimeric-anti staphylococcal monoclonal antibody for prevention of coagulase negative staphylococcal infection in very low birth weight infants: preliminary report. Pediatric Academic Societies Annual Meeting, Seattle, Washington (2003).